PPAR-γ ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells

Cancer Letters

Volumn 236, Issue 1, 2006, Pages 133-141

  Núñez, Nomelí P ^a   Liu, Huaitian ^b   Meadows, Gary G ^a  

^a The Pharmacology and Toxicology Graduate Program   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amino acid; Apoptosis; Breast cancer; Melanoma; PPAR; Prostate cancer

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; AMINO ACID; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; DRUG DERIVATIVE; LIGAND; METHIONINE; PHENYLALANINE; PROSTAGLANDIN D2; TYROSINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; HUMAN; HUMAN CELL; INFANT; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; BREAST TUMOR; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MALE; MELANOMA; METHIONINE; PHENYLALANINE; PPAR GAMMA; PROSTAGLANDIN D2; PROSTATIC NEOPLASMS; THIAZOLIDINEDIONES; TYROSINE;

EID: 33745404148     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.009     Document Type: Article

References (31)

1. Sporn M.B., Suh N., and Mangelsdorf D.J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol. Med. 7 (2001) 395-400
2. Lea M.A., Sura M., and Desbordes C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res. 24 (2004) 2765-2771
3. Mössner R., Schulz U., Kruger U., Middel P., Schinner S., Fuzesi L., et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J. Invest. Dermatol. 119 (2002) 576-582
4. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58 (1998) 3344-3352
5. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., et al. Ligands for peroxisome proliferator-activated receptor g and retinoid acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. 95 (1998) 8806-8811
6. Brockman J.A., Gupta R.A., and Dubois R.N. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 (1998) 1049-1055
7. Xin X., Yang S., Kowalski J., and Gerritsen M.E. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274 (1999) 9116-9121
8. Yoshizumi T., Ohta T., Ninomiya I., Terada I., Fushida S., Fujimura T., et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int. J. Oncol. 25 (2004) 631-639
9. Strakova N., Ehrmann J., Dzubak P., Bouchal J., and Kolar Z. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J. Pharmacol. Exp. Ther. 309 (2004) 1239-1247
10. Pelayo B.A., Fu Y.-M., and Meadows G.G. Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors. Clin. Exp. Metastasis 17 (1999) 841-848
11. Fu Y.-M., Yu Z.-X., Ferrans V.J., and Meadows G.G. Tyrosine and phenylalanine restriction induces G0/G1 cell cycle arrest in murine melanoma in vitro and in vivo. Nutr. Cancer 29 (1997) 104-113
12. Cellarier E., Durando X., Vasson M.P., Farges M.C., Demiden A., Maurizis J.C., et al. Methionine dependency and cancer treatment. Cancer Treat. Rev. 29 (2003) 489-499
13. Pelayo B.A., Fu Y.-M., and Meadows G.G. Decreased tissue plasminogen activator and increased plasminogen activator inhibitors are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine. Int. J. Oncol. 18 (2001) 877-883
14. Fu Y.-M., Yu Z.X., Li Y.-Q., Ge X., Sanchez P.J., Fu X., and Meadows G.G. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutr. Cancer 45 (2003) 60-73
15. Meadows G.G., Ge X., Zhang H., Oros D.E., and Fu Y.-M. Inhibition of invasion and metastasis during specific amino acid restriction associated with metastasis suppressor and other gene changes. In: Welch D.R. (Ed). Cancer Metastasis Related Genes (2002), Kluwer, The Netherlands 2191-2208
16. Elstad C.A., Meadows G.G., and Abdallah R.M. Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction. Clin. Exp. Metastasis 8 (1990) 393-416
17. Abdallah R.M., Starkey J.R., and Meadows G.G. Dietary restriction of tyrosine and phenylalanine: inhibition of metastasis of three rodent tumors. J. Natl. Cancer Inst. 78 (1987) 759-766
18. Pierson H.F., and Meadows G.G. Influence of supplemental ascorbate on the antitumor activity of 5-hydroxydopa, a purported cytotoxic metabolite. Cancer Lett. 29 (1985) 157-168
19. Meadows G.G., Abdallah R.M., and Starkey J.R. Interaction between specific dietary factors and experimental chemotherapy of metastatic melanoma. Cancer Chemother. Pharmacol. 16 (1986) 229-236
20. Elstad C.A., Thrall B.D., Raha G., and Meadows G.G. Tyrosine and phenylalanine restriction sensitizes adriamycin-resistant P388 leukemia cells to adriamycin. Nutr. Cancer 25 (1996) 47-60
21. Meadows G.G., Pierson H.F., Abdallah R.M., and Desai P.R. Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy. Cancer Res. 42 (1982) 3056-3063
22. Norris J.R., Meadows G.G., Massey L.K., Starkey J.R., Sylvester D.M., and Liu S.-Y. Tyrosine- and phenylalanine-restricted formula diet augments immunocompetence in healthy humans. Am. J. Clin. Nutr. 51 (1990) 188-196
23. Poirson-Bichat F., Gonfalone G., Bras-Gonçalves R.A., Dutrillaux B., and Poupon M.F. Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. Br. J. Cancer 75 (1997) 1605-1612
24. Epner D.E., Morrow S., Wilcox M., and Houghton J.L. Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr. Cancer 42 (2002) 158-166
25. Nwankwo J.O., and Robbins M.E. Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot. Essent. Fatty Acids 64 (2001) 241-245
26. Spiegelman B.M. PPARgamma in monocytes: less pain, any gain?. Cell 93 (1998) 153-155
27. Forman B.M., Tonontoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-γ. Cell 83 (1995) 803-812
28. Yu Z.-X., Biro S., Fu Y.-M., Sanchez J., Smale G., Sasse J., et al. Localization of basic fibroblast growth factor in bovine endothelial cells: Immunohistochemical and biochemical studies. Exp. Cell Res. 204 (1993) 247-259
29. Hussain M.H., Blumenstein B., Eisenberger M., and Crawford E.D. Southwest Oncology Group studies in hormone-refractory prostate cancer. Semin. Oncol. 23 (1996) 24-27
30. Pawlik T.M., and Sondak V.K. Malignant melanoma: current state of primary and adjuvant treatment. Crit. Rev. Oncol. Hematol. 45 (2003) 245-264
31. Skog S., He Q., Khoshnoud R., Fornander T., and Rutqvist L.E. Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour Biol. 25 (2004) 41-47